1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : PHARMACEUTICALS
  4. GLAXOSMITHKLINE PHARMACEUTICALS LTD.
GlaxoSmithKline Pharmaceuticals Ltd.
NSE: GLAXO | BSE: 500660

GlaxoSmithKline Live Share Price Today, Share Analysis and Chart

Expensive Performer
aboutGlaxoSmithKline Pharmaceuticals Limited (GSK India) is a leading biopharmaceutical entity and a subsidiary of the global healthcare company GSK plc. With a presence in India spanning over a century, the company holds a significant market position in ... Read More
Ask AI about GlaxoSmithKline
2494.30-20.80(-0.83%)
58,144
NSE+BSE Volume

NSE 30 Oct, 2026 3:31 PM (IST)

Portfolio

Alert

My Notes

Board Meeting
The next board meeting for GlaxoSmithKline is on 03 Nov 2026 for the purpose of Quarterly Results See details
Loading...
- / 100
- / 100
52.5 / 100
Expensive PerformerThese stocks are strong in quality but with mid-range technicals. Their valuations are expensiveView SimilarEmbed DVM
Analyst Price Target
-

12

S

11

W

6

O

1

T

SWOT Analysis

Check Before You Buy

VIEW FULL CHECKLIST

High rank

14Positive9Negative

Pass in checklist60.9%

045
55
100

PE Valuation Check

Right Now
Undervalued
12.9%
1 Year Forward
Undervalued
23.1%
INSIGHTGlaxoSmithKline is undervalued at both current PE and future earnings estimates.

GlaxoSmithKline Stock Price Analysis

Day Price Range

-0.8% 1 Day return
2494.3 (LTP)
2,479.32,528.9
LowHigh

Week Price Range

3.7% 1 Week return
2494.3 (LTP)
2,398.12,540
LowHigh

Month Price Range

-10.4% 1 Month return
2494.3 (LTP)
2,344.12,813.6
LowHigh

52 Week Price Range

-4.9% 1 Year return
2494.3 (LTP)
2,088.13,120.7
LowHigh
View full Price History/Seasonality

GlaxoSmithKline Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Miss

GlaxoSmithKline's Revenue was lower than average estimate 2 times in past 3 years

EPS forecast

CURRENT EPS
61.2
AVG. ESTIMATE
68.8
LOW ESTIMATE
67.1
HIGH ESTIMATE
70.4
CURRENT EPS
AVG. ESTIMATE
Hit

EPS is expected to grow by 12.5% in FY27

Consensus Recommendation

4 ANALYST Recommendations
BUY

The consensus recommendation from 4 analysts for GlaxoSmithKline is BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get
Upgrade Now

GlaxoSmithKline Technical Analysis

GlaxoSmithKline EMA & SMA

Bearish-6
1 bullish, 7 bearish
Bullish1
Bearish7
5 Day2489.4
10 Day2498.0
12 Day2507.5
20 Day2554.1
26 Day2585.1
50 Day2640.1
100 Day2623.1
200 Day2591.2

GlaxoSmithKline Delivery And Volume

Daily Avg. Delivery Volume %
30 Oct, 202664.7%
Week65.9%
Month51.3%
Legend
Positive IndicatorNeutral IndicatorNegative Indicator

GlaxoSmithKline Resistance and Support

2500.83
Pivot
First Resistance2522.4
Second Resistance2550.4
Third Resistance2572.0
First Support2472.8
Second Support2451.2
Third Support2423.2
Day RSI38.7
Day MACD-77.6
Day MFI54.3
Day MACD Signal Line-84.7

GlaxoSmithKline Beta

1 Month1
1 Year0.5
3 Month0.4
3 Year0.6

GlaxoSmithKline Price Change Analysis

↓-10.4%
Over 1 Month
LowHigh
2344.12813.6
↓-4.5%
Over 3 Months
LowHigh
2344.13120.7
↑5.4%
Over 6 Months
LowHigh
2088.13120.7
↓-4.9%
Over 1 Year
LowHigh
2088.13120.7
All Technicals →

GlaxoSmithKline Shareholding Pattern/ Ownership

Shareholding Summary

Sep 2026
 
NameCategorySharesShares %
Glaxo Group LimitedPromoter60,970,50036.0 %
Nippon Life India Trustee Ltd-A/C Nippon India NifDii1,776,6231.1 %

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

All Shareholding details

GlaxoSmithKline Deals - Insider, Bulk, Block and SAST

Client NameDeal TypeActionDateAvg. PriceQuantityExchange
ISHARES CORE EMERGING MARKETS MAURITIUS COBlockSell17 Oct 20221378.6580,615BSE
ISHARES INDIA SC MAURITIUS COMPANYBlockSell17 Oct 20221378.6511,841BSE
ISHARES CORE MSCI EMERGING MARKETS ETFBlockPurchase17 Oct 20221378.6580,615BSE
ISHARES MSCI INDIA SMALL-CAP ETFBlockPurchase17 Oct 20221378.6511,841BSE
ISHARES CORE EMERGING MARKETS MAURITIUS COBlockSell11 Oct 20221393.4577,734BSE
ISHARES INDIA SC MAURITIUS COMPANYBlockSell11 Oct 20221393.4511,417BSE
ISHARES CORE MSCI EMERGING MARKETS ETFBlockPurchase11 Oct 20221393.4577,734BSE
ISHARES MSCI INDIA SMALL-CAP ETFBlockPurchase11 Oct 20221393.4511,417BSE
ISHARES CORE EMERGING MARKETS MAURITIUS COBlockSell03 Oct 20221424.4077,439NSE
ISHARES INDIA SC MAURITIUS COMPANYBlockSell03 Oct 20221424.4011,373NSE
All deals
All insider trades

GlaxoSmithKline Corporate Actions

GlaxoSmithKline Dividend history and yield

GlaxoSmithKline dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track GlaxoSmithKline dividend yield over time.

#Ex-Date
Dividend AmountDividend TypeRecord DateInstrument Type
129 May 2026
57FINAL29 May 2026Equity Share
230 May 2025
42FINAL30 May 2025Equity Share
307 Nov 2024
12INTERIM07 Nov 2024Equity Share
431 May 2024
32FINAL31 May 2024Equity Share
530 Jun 2023
32FINAL30 Jun 2023Equity Share

GlaxoSmithKline Bonus shares

GlaxoSmithKline bonus history along with announcement, record, ex-bonus dates, and bonus ratios.

#Ex-Date
Bonus RatioRecord Date
111 Sep 2018
1:113 Sep 2018

GlaxoSmithKline Board Meetings

GlaxoSmithKline past and upcoming board meetings.

#Ex-Date
PurposeNotes
103 Nov 2026
Quarterly Results-
203 Aug 2026
Quarterly Results-
313 May 2026
Audited Results & Dividend-
409 Feb 2026
Quarterly Results-
506 Nov 2025
Quarterly Results-

GlaxoSmithKline Rights issue

GlaxoSmithKline rights issue history, along with record, ex-rights dates, and rights ratios.

#Ex-Date
RatioFace ValuePremiumRecord Date
121 May 1993
1.0:5.0-5515 Jun 1993
All Corporate Actions

GlaxoSmithKline Research Reports

GlaxoSmithKline research reports with share price targets, and buy/hold/sell recommendations from top brokers.

#
Date
Broker NameTargetPrice When RecommendedTypeUpsideChange Since RecommendationLinks
102 Aug 2026Motilal Oswal28702662.3Neutral7.8%-6.31%pdf
208 Nov 2025ICICI Securities Limited
Reco
25002587.9Hold-3.4%-3.62%pdf
301 Aug 2025Motilal Oswal
Target
30002936.5Neutral2.16%-15.06%pdf
413 May 2025ICICI Securities Limited
Reco
Target
26002878.8Sell-9.68%-13.36%pdf
504 Aug 2024Motilal Oswal
Target
26202763.95Neutral-5.21%-9.76%pdf
All Reports of GlaxoSmithKline

GlaxoSmithKline Corporate Filings

GlaxoSmithKline BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.

DateAnnouncement TitleDetailsLinks
28 Oct 2026
GlaxoSmithKline Pharmaceuticals Ltd - 500660 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
As per attachment
PDF
13 Oct 2026
GlaxoSmithKline Pharmaceuticals Ltd - 500660 - Board Meeting Intimation for To Consider, Approve And Take On Record The Un-Audited Financial Results For The Second Quarter & Half Year Ended 30Th September 2026.
Glaxosmithkline Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve As per attachment
PDF
12 Oct 2026
GlaxoSmithKline Pharmaceuticals Ltd - 500660 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
As per attachment
PDF
25 Sep 2026
GlaxoSmithKline Pharmaceuticals Ltd - 500660 - Closure of Trading Window
As per attachment
PDF
15 Sep 2026
GlaxoSmithKline Pharmaceuticals Ltd - 500660 - Shareholder Meeting / Postal Ballot-Outcome of Postal Ballot
As per attachment
PDF
VIEW ALL

GlaxoSmithKline DocumentsAsk MarketMind AI

GlaxoSmithKline Earnings Call

GlaxoSmithKline earnings calls, including management commentary and AI-generated summaries.

DateTitleLinks
17 Feb 2025GLAXOSMITHKLINE PHARMACEUTICALS LTD. - 500660 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeLink
15 Feb 2025GLAXOSMITHKLINE PHARMACEUTICALS LTD. - 500660 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeLink
30 Oct 2024GLAXOSMITHKLINE PHARMACEUTICALS LTD. - 500660 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeLink
29 Oct 2024GLAXOSMITHKLINE PHARMACEUTICALS LTD. - 500660 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeLink
08 Aug 2024GLAXOSMITHKLINE PHARMACEUTICALS LTD. - 500660 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeLink
view all

GlaxoSmithKline Annual Reports

GlaxoSmithKline financials, including annual results, balance sheets, and cash flow statements.

DateReport TitleLinks
2026Annual Report Mar-2026Link
2025Annual Report Mar-2025Link
2024Annual Report Mar-2024Link
2023Annual Report Mar-2023Link
2022Annual Report Mar-2022Link

GlaxoSmithKline Investor Presentations

GlaxoSmithKline investor presentations, including business updates, financial insights, and strategic initiatives.

DateReport TitleLinks
03 Aug 2026GlaxoSmithKline Pharmaceuticals Ltd - 500660 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeLink
13 May 2026GlaxoSmithKline Pharmaceuticals Ltd - 500660 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationLink
06 Nov 2025GlaxoSmithKline Pharmaceuticals Ltd - 500660 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
01 Aug 2025GlaxoSmithKline Pharmaceuticals Ltd - 500660 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
13 May 2025GlaxoSmithKline Pharmaceuticals Ltd - 500660 - Announcement under Regulation 30 (LODR)-Investor PresentationLink

GlaxoSmithKline - Company Profile

GlaxoSmithKline Management Structure

GlaxoSmithKline management structure with salaries, total experience, and qualifications.

NAMEDESIGNATIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Mr. Carson DaltonExecutive Vice President(Communications,Government Affairs)-Mar 26
Ms. Vibhuti GuptaVice President(Commercial Operations,Strategy)-Mar 26
Mr. Rishikesh JaiwantExecutive Vice President(Supply Chain Operation)-Mar 26
Dr. (Ms.) Shalini MenonExecutive Vice President(Medical Affairs)-Mar 26
Ms. Sharmishta MitraVice President(Paediatric Services,Vaccines)-Mar 26
A A NadkarniVice President(Real Estate,Administration),Company Secretary,Compliance Officer-Mar 26
Mr. Amit PandeyExecutive Vice President(Legal.)-Mar 26
Mr. Omkar ParnandiwarVice President,Head(Vaccines)-Mar 26
Ms. Aparajita RajputVice President(Technology)-Mar 26
Dr. (Ms.) Simrat SohalVice President(Ethics,Compliance)-Mar 26
Ms. S. ChoudharyExecutive Vice President(Regulatory Affairs)-Mar 26
Mr. H. TrehanExecutive Vice President(Human Resources)-Mar 26
Mr. V. SwarupExecutive Vice President(General Medicines)-Mar 26
Ronojit BiswasWhole Time Director,Chief Financial Officer-Mar 26

GlaxoSmithKline Board of Directors

GlaxoSmithKline Board of directors with salaries, total experience, and qualifications.

NAMEPOSITIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Bhushan AkshikarManaging Director1136.58Mar 26
Renu S. KarnadChairman & Non Executive Dir.33Mar 26
Manu AnandIndependent Non Exe. Director28Mar 26
Somasundaram PalamadairamaswamyIndependent Non Exe. Director27Mar 26
Anup WadhawanIndependent Non Exe. Director25.5Mar 26
Sunita MaheshwariIndependent Non Exe. Director24.5Mar 26
Ronojit BiswasWhole Time Director & CFO-Mar 26
A A NadkarniVP / Company Secretary / Compliance Officer-Mar 26
Karine J F NatlandNon Executive Director-Mar 26

GlaxoSmithKline Brands

Brands owned by GlaxoSmithKline

LOGOBRAND NAME
Zentel Albendazole
Betnovate C
Cetzine
Neosporin Antibiotic Ointment (Skin)
LOGOBRAND NAME
CCM
Ceftum
Celin Tablets and Celin Chewable Tablets
Clindoxyl
LOGOBRAND NAME
Neosporin-H Ear Drops
Neosporin Antibiotic Powder
Neosporin-H eye and skin Ointment
Nucala
LOGOBRAND NAME
Zoderm - E
Zovirax
Zyloric
Zupar
Website: www.gsk-india.com

About the company - Business Profile

GlaxoSmithKline Pharmaceuticals Limited (GSK India) is a leading biopharmaceutical entity and a subsidiary of the global healthcare company GSK plc. With a presence in India spanning over a century, the company holds a significant market position in the private vaccines and dermatology segments. It operates within the healthcare industry, focusing on the discovery, development, and distribution of a diverse range of pharmaceutical products including anti-infectives, pain management, respiratory, and specialty medicines. GSK India plays a critical role in the Indian healthcare landscape through its "Make in India" initiatives, locally manufacturing a broad range of general medicines while importing advanced vaccines and specialty treatments.

Key Points

  • Key Facts:
    • Founded: 1924 (Centenary year celebrated in 2024-25).
    • Headquarters: GSK House, Worli, Mumbai, Maharashtra.
    • Parent Company: GSK plc (through various subsidiaries including Glaxo Group Limited, U.K.).
    • Stock Listing: Listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE).
  • Operations and Resources:
    • Manufacturing: Operates a primary manufacturing facility in Ambad, Nashik.
    • Distribution: Extensive network covering over 1,400 towns across India.
    • Assets: In 2021, the global parent inaugurated a Global Capability Centre (GCC) in India to support various business functions.
  • Ownership:
    • Promoter Holding: As of March 31, 2024, the promoter group (GSK plc subsidiaries) held 75% of the equity. Major holders include Glaxo Group Limited (35.99%) and GlaxoSmithKline Pte Limited, Singapore (28.10%).
  • Market Significance:
    • The company is a market leader in the private vaccine market and dermatologicals.
    • It maintains a leadership position in the anti-infectives segment.
  • Business Model and Strengths:
    • GSK India utilizes a hybrid model of local manufacturing and strategic imports.
    • The company is proficient in managing high-volume general medicine portfolios like Calpol (pain) and Augmentin (anti-infective) while scaling specialty portfolios like Shingrix (shingles vaccine) and Nucala (respiratory).
  • Revenue Breakdown (FY 2024-25):
    • Total Revenue from Operations: Rs. 3,723.49 Crores.
    • Other Income: Rs. 142.56 Crores.
    • Segmental Reporting: The company operates in a single reportable segment, which is Pharmaceuticals.
  • Key Products and Impact:
    • Anti-Infectives: Augmentin and Ceftum impacted approximately 82 million patients.
    • Pain Management: Calpol and Calpol T were used by over 104 million patients.
    • Respiratory: Nucala, Trelegy Ellipta, and Seretide served approximately 60,000 patients suffering from asthma and COPD.
    • Vaccines: Shingrix, Havrix, Fluarix Tetra, and Infanrix Hexa provided protection to 3.3 million adults and children.
    • Dermatology: Betnovate, T-Bact, and Tenovate treated 23.7 million patients.
  • Innovation and Sustainability:
    • Renewable Energy: Acquired a 26% stake in Clean Max Galapagos Private Limited (a Special Purpose Vehicle) to supply 4.95 MWp of renewable energy for its Maharashtra operations.
    • Digitalization: Focus on data-driven patient and HCP engagement through omnichannel platforms.
  • Employee Information:
    • Headcount: Employs over 3,100 people.
    • Recognition: Certified as a Great Place to Work for 2025-26 and recognized among India's Best Workplaces for Women.
  • Strategic Initiatives and Outlook:
    • Continuous focus on expanding the specialty medicine and vaccine portfolio.
    • Monitoring the implementation of the new Labour Code (Working Conditions Code, 2020), which is expected to impact employee benefit expenses (an estimated incremental impact of Rs. 11.82 Crores was noted for the nine months ended December 2025).

References

  1. Annual Report May 2025
  2. Annual Report May 2024
  3. Earnings Result Nov 2025
  4. Earnings Result Feb 2026

GlaxoSmithKline FAQ

GlaxoSmithKline today is trading in the red, down by 0.83% at ₹2,494.3.
GlaxoSmithKline is currently trading down 0.83% on an intraday basis. In the past week the stock rose 3.73%. Stock has been down 4.46% in the past quarter and fell 4.86% in the past year. You can view this in the share price history/seasonality section.
GlaxoSmithKline is listed on NSE with the ticker GLAXO and on BSE as 500660. It's currently trading on NSE at a share price of ₹2,494.3 and on BSE with a share price of ₹2,505.
The market cap of GlaxoSmithKline is ₹42,254.94 Cr. as of Oct 30, 2026.
GlaxoSmithKline announced a FINAL dividend of 570% which equals ₹57 in May 29, 2026.The last three ex-dates for GlaxoSmithKline were May 30, 2025, Nov 07, 2024 and May 31, 2024. To view the full dividend history of GlaxoSmithKline click here.
GlaxoSmithKline has never issued stock splits, but it has issued 1 bonus shares since its BSE/NSE listing. The latest announcement for GlaxoSmithKline bonus shares was on Sep 11, 2018 at a ratio of 1:1.
GlaxoSmithKline reported ₹982.2 Cr. in revenue, ₹237.18 Cr. in net profit, and ₹339.26 Cr. in EBITD as of Aug 03, 2026 for Q1 FY26-27.
According to the predictions of 4 analysts, the share price prediction for GlaxoSmithKline is ₹3,097.25 with an upside of 24%.
The PE ratio of GlaxoSmithKline is 39.56 as of Oct 30, 2026.
The PB ratio of GlaxoSmithKline is 16.87 as of Oct 30, 2026.
You can view the latest analyst reports on the GlaxoSmithKline reports dashboard. Either click on the Reports tab on this page's sub-header or click here to be directed to the dashboard.
You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.
Ask AI
×